Koyfin Home > Directory > Health Care > Acceleron Pharma > EBIT

Acceleron Pharma EBIT Chart (XLRN)

Acceleron Pharma annual/quarterly EBIT from 2012 to 2020. Earnings before interest and taxes measures the profit a company generates from its operations, making it synonymous with operating profit. By ignoring tax and interest expenses, it focuses solely on a company's ability to generate earnings from operations, ignoring variables such as the tax burden and capital structure.
  • Acceleron Pharma EBIT for the quarter ending June 06, 2020 was $-19m a -158.67% increase of 30m year over year
  • Acceleron Pharma EBIT for the last 12 months ending June 06, 2020 was $-145m a -1.85% increase of 3m year over year
  • Acceleron Pharma Annual EBIT for 2019 was $-136m a 8.82% decrease of -12m from 2018
  • Acceleron Pharma Annual EBIT for 2018 was $-124m a 11.60% decrease of -14m from 2017
  • Acceleron Pharma Annual EBIT for 2017 was $-110m a 39.89% decrease of -44m from 2016
Other Income Statement Metrics:
  • Acceleron Pharma EBITDA for the quarter ending December 12, 2018 was $-36m a 25.58% decrease of -9m year over year
  • Acceleron Pharma Net Income for the quarter ending December 12, 2018 was $-35m a 24.52% decrease of -9m year over year
  • Acceleron Pharma Total Revenue for the quarter ending September 09, 2018 was $3m a -13.72% decrease of 0m year over year
View Chart On Koyfin

Quarterly XLRN EBIT Data

06/2020$-19m
03/2020$-52m
12/2019$-26m
09/2019$-49m
06/2019$-21m
03/2019$-41m
12/2018$-37m
09/2018$-30m
06/2018$-30m
03/2018$-28m

Annual XLRN EBIT Data

2019$-136m
2018$-124m
2017$-110m
2016$-66m
2015$-61m
2014$-50m
2013$7m
2012$-29m
2011$39m